0H8I

Accuray LSE:0H8I Stock Report

Last Price

US$2.43

Market Cap

US$222.3m

7D

2.0%

1Y

-40.7%

Updated

20 Jan, 2023

Data

Company Financials +

0H8I Stock Overview

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the Americas, Europe, the Middle East, India, Africa, Japan, China, and rest of the Asia Pacific region.

0H8I fundamental analysis
Snowflake Score
Valuation2/6
Future Growth4/6
Past Performance0/6
Financial Health4/6
Dividends0/6

My Notes

New

Notes are coming soon

Accuray Incorporated Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Accuray
Historical stock prices
Current Share PriceUS$2.43
52 Week HighUS$4.13
52 Week LowUS$1.85
Beta1.5
1 Month Change24.56%
3 Month Changen/a
1 Year Change-40.66%
3 Year Changen/a
5 Year Changen/a
Change since IPO-56.99%

Recent News & Updates

Recent updates

Shareholder Returns

0H8IGB Medical EquipmentGB Market
7D2.0%-1.5%-0.8%
1Y-40.7%-10.2%-7.1%

Return vs Industry: 0H8I underperformed the UK Medical Equipment industry which returned -9.4% over the past year.

Return vs Market: 0H8I underperformed the UK Market which returned -6.3% over the past year.

Price Volatility

Is 0H8I's price volatile compared to industry and market?
0H8I volatility
0H8I Average Weekly Movementn/a
Medical Equipment Industry Average Movement7.6%
Market Average Movement5.1%
10% most volatile stocks in GB Market10.8%
10% least volatile stocks in GB Market2.6%

Stable Share Price: Insufficient data to determine 0H8I's volatility over the past 3 months.

Volatility Over Time: Insufficient data to determine 0H8I's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
19901,044Suzanne Winterhttps://www.accuray.com

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the Americas, Europe, the Middle East, India, Africa, Japan, China, and rest of the Asia Pacific region. It offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate. The company also provides the TomoTherapy System, including the Radixact System, which allows for integrated radiation treatment planning, delivery, and data management, enabling clinicians to deliver ultra-precise treatments to approximately 50 patients per day.

Accuray Incorporated Fundamentals Summary

How do Accuray's earnings and revenue compare to its market cap?
0H8I fundamental statistics
Market CapUS$222.26m
Earnings (TTM)-US$9.77m
Revenue (TTM)US$418.96m

0.5x

P/S Ratio

-22.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
0H8I income statement (TTM)
RevenueUS$418.96m
Cost of RevenueUS$263.93m
Gross ProfitUS$155.03m
Other ExpensesUS$164.80m
Earnings-US$9.77m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

Feb 01, 2023

Earnings per share (EPS)-0.10
Gross Margin37.00%
Net Profit Margin-2.33%
Debt/Equity Ratio375.2%

How did 0H8I perform over the long term?

See historical performance and comparison